Space Force Awards SpaceX $4.16B to Build Orbital Airborne Surveillance
The Space Force awarded SpaceX a $4.16 billion contract to deploy space-based moving target indicator satellites by 2028, shifting a core ISR mission from aircraft to orbit and threatening legacy airborne platforms.
Groq raises $650M to become inference cloud after Nvidia deal
Groq pivots from chip maker to cloud services after licensing its LPU to Nvidia for $20B, raising $650M from existing backers to build inference infrastructure.
Atomic rethinks version control for AI agents writing code at machine speed
Atomic Software raised $2.5M to build version control designed for AI coding agents, replacing Git's human-centric model with patch theory and provenance tracking.
Draganfly, F4 Defense win Army Research Lab counter-drone contract
Draganfly and F4 Defense International selected by DEVCOM Army Research Lab to develop integrated counter-UAS platform combining tethered surveillance, AI tracking, and coordinated defeat capabilities.
Firestorm Labs wins $100M Air Force contract for 3D-printed drones
Firestorm Labs lands $100M USAF contract for Tempest 50 sUAS, gaining Air Force backing for expeditionary additive manufacturing that could compress drone production timelines and costs by 80 percent.
Core Lightning v26.04 RC2: Splicing Graduates to Production
Core Lightning v26.04 RC2 promotes splicing from experimental to stable user-facing commands, enabling channel resizing without downtime. This moves Lightning toward true 'one-balance' wallets and cuts transaction costs in half.
Core Lightning v26.04rc1 Debuts splicein and spliceout Commands
Core Lightning v26.04rc1, tagged March 26 2026, introduces high-level splicein and spliceout commands that abstract years of low-level splicing complexity into operator-ready RPC calls, marking a structural maturation of Lightning channel management.
FDA Approves Rocket Pharma's KRESLADI: First Gene Therapy for LAD-I
Rocket Pharmaceuticals secured FDA accelerated approval on March 26, 2026 for KRESLADI, the first gene therapy for severe LAD-I, reversing a 2024 manufacturing rejection and unlocking a Rare Pediatric Disease Priority Review Voucher worth $80M–$155M.